Race Oncology Ltd. (AU:RAC) has released an update.
Race Oncology Ltd. has announced a change in director Dr. Sergio Scrofani’s interest, with the acquisition of 58,446 unlisted options. These options are exercisable at $2.05 and will expire on November 25, 2028, following shareholder approval. This move may interest investors tracking executive decisions within the company.
For further insights into AU:RAC stock, check out TipRanks’ Stock Analysis page.